Clinical Management and Outcomes of Primary Ovarian Leiomyosarcoma
Key facts
- Where
- Avellino, Catania, Milan, Modena, Monza, Naples, Parma, Reggio Emilia, and Verona, ItalySee the 10 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT06749600, who can take part
Where in Italy
- Malzoni - AvellinoAvellino, ItalyTaking people
- Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco" - CataniaCatania, ItalyTaking people
- IRCCS Ospedale San RaffaeleMilan, ItalyTaking people
- AOU Policlinico di ModenaModena, ItalyTaking people
- Fondazione IRCCS San Gerardo dei TintoriMonza, ItalyTaking people
- IRCCS Istituto Nazionale Tumori Fondazione PascaleNaples, ItalyTaking people
- Università degli studi di Napoli Federico IINaples, ItalyTaking people
- Azienda Ospedaliero Universitaria di Parma - S.C. Ostetricia e GinecologiaParma, ItalyTaking people
- Azienda USL IRCCS di Reggio EmiliaReggio Emilia, ItalyTaking people
- Ospedale "Sacro Cuore"Verona, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Azienda USL Reggio Emilia - IRCCS
- Trial code
- NCT06749600
- Record updated
- 5 May 2026
- Original description
This observational study aims to gather comprehensive data on primary ovarian leiomyosarcoma (POLMS). This extremely rare malignancy accounts for less than 3% of primary ovarian malignancies and has an incidence of only 1% among ovarian cancers. This national, retrospective and prospective multicenter study will collect and analyze historical cases of POLMS with remote diagnoses accessed through clinical case reviews and newly identified cases. The study aims to expand a previously identified series of 113 cases described in the literature, uncovering patterns in diagnosis, treatment, and outcomes and ultimately establishing evidence-based guidelines for the optimal management of this rare and aggressive cancer.Read full original descriptionShow less
This observational study aims to gather comprehensive data on primary ovarian leiomyosarcoma (POLMS). This extremely rare malignancy accounts for less than 3% of primary ovarian malignancies and has an incidence of only 1% among ovarian cancers. This national, retrospective and prospective multicenter study will collect and analyze historical cases of POLMS with remote diagnoses accessed through clinical case reviews and newly identified cases. The study aims to expand a previously identified series of 113 cases described in the literature, uncovering patterns in diagnosis, treatment, and outcomes and ultimately establishing evidence-based guidelines for the optimal management of this rare and aggressive cancer.
Inclusion: Diagnosis of primary leiomyosarcoma of the ovary; Patients diagnosed with POLMS for whom data relating to diagnosis and treatment are available; Aged between 18 and 99 years.
Exclusion: All patients with other forms of ovarian sarcoma (rhabdomyosarcomas, fibrosarcomas, stromal cell sarcomas) and patients diagnosed with leiomyosarcoma of the uterus will be excluded.